Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial
Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan · 2026
Read Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial by Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13341324.txt.
Description
Ping Jin and colleagues tested a new drug, BGM0504, in 2026 in Chinese adults with type 2 diabetes, comparing it with semaglutide. The multicentre, randomised, placebo controlled trial assigned 64 adults to BGM0504 at 5, 10, or 15 milligrams, placebo, or semaglutide 1 milligram, each once weekly for twelve weeks. Safety, drug levels, drug effects, and efficacy were all tracked.
The main endpoint was change in HbA1c from baseline, with fasting glucose, two hour glucose, and body weight as secondary endpoints. Early phase trials of this kind test whether a new drug merits larger trials. The comparison with semaglutide gives a first read on relative potency and tolerability.
Catalog record
| CREATOR | Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |